Healthcare Australian Community

My view: Ansell (ASX: ANN) is a quality, mid-risk company suited for a long-term investment. It operates within a stable and expanding TAM, supported by rising global safety and healthcare demand.Read more

What do I think the business will look like in 5 years time, and why? I believe Pro Medicus will still be focused on providing medical imaging software and radiology workflow solutions to large hospitals and healthcare networks.Read more

There's a telling anecdote about Pro Medicus that doesn't appear in any investor presentation. Radiologists at top US hospitals have started demanding it as a condition of employment — they simply won't join institutions that don't run Visage, the company's flagship imaging platform.Read more

4DMedical is the first non-invasive, contrast free imaging technology for the lung scanning. New CT:VQ lung scanner is the first technology of its kind and is rapidly being adopted by clinics and big name KOL's in America.Read more

The quarterly release indiates the company is getting through to profitability and cashflow sustainability. Management team seems to have done a good job across the board – cash, price, volume, renegotiations, cost control, efficiency, etc.Read more

Pro Medicus (ASX: PME) is an Australian company that develops medical imaging software under its Visage product range. Leading medical institutions including NYU Langone, UCSF, and Mass General Brigham have publicly or semi-publicly praised the platform—often via PME-issued press releases or interviews.Read more

Monash IVF ( ASX: MVF ) Monash IVF Group Limited is a leading provider of assisted reproductive services in Australia and Malaysia. With over 50 years of experience, the company has been instrumental in pioneering fertility treatments, including achieving Australia's first IVF birth and the world's first pregnancy from a frozen embryo.Read more

Key Takeaways Expansion of high-margin genetic tests and innovative automation positions the company for outsized revenue and earnings growth ahead of market expectations. Monetizing previously unfunded test volumes and disciplined portfolio management will drive strong cash generation and safeguard long-term profitability.Read more

Key Takeaways Accelerated adoption, regulatory shifts, and digital innovations could drive recurring revenue and margin growth far ahead of current analyst expectations. Strategic manufacturing integration and potential acquisitions may rapidly expand market reach, cost advantages, and diversification within infection prevention.Read more